BridgeMD
New treatment option for Upper Respiratory Disease
Official title Immune Defense Protein Impact On Respiratory Immune Outcomes
ClinicalTrials.gov ID: NCT07431840
What this study is testing
- What it's testing
- The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older. Healthy volunteers may be eligible.
You may be able to join if
- Age 60 years and older
- Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
- Able to read and understand English.
- Able to read, understand, and provide informed consent.
- Able to use a personal smartphone device and download Chloe by People Science.
You likely can't join if
- Any potential participants who:
- Do not have a personal smartphone, internet access, or unwilling to download Chloe.
- Already in an immunocompromised state, including: A. Infectious Causes
- HIV/AIDS
- Chronic hepatitis B or C (advanced stages)
- Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
See the full eligibility criteria
- Age 60 years and older
- Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
- Able to read and understand English.
- Able to read, understand, and provide informed consent.
- Able to use a personal smartphone device and download Chloe by People Science.
- Able to receive shipment of the product at an address within the United States.
- Any potential participants who:
- Do not have a personal smartphone, internet access, or unwilling to download Chloe.
- Already in an immunocompromised state, including: A. Infectious Causes
- HIV/AIDS
- Chronic hepatitis B or C (advanced stages)
- Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
- Leukemia (e.g., AML, ALL, CLL)
- Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
- Multiple Myeloma
- Any metastatic cancer receiving chemotherapy C. Immunosuppressive Therapy: Participants on:
- Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
- Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
- Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)
- mTOR inhibitors (e.g., sirolimus)
- JAK inhibitors (e.g., tofacitinib)
- Chemotherapy or radiation therapy
- Anti-rejection meds post-organ transplant D. Transplant Patients
- Solid organ transplant (kidney, liver, heart, lung)
- Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus (SLE)
- Psoriasis or Psoriatic Arthritis
- Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis)
- Multiple Sclerosis (especially on disease-modifying therapies)
- Other Concomitant Conditions and Therapies:
- Any investigational therapies or treatments within 30 days prior to enrollment.
- Known diagnosis of Asthma and/or COPD
- Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
- Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes
- Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes
- Use of cannabis-containing products daily
- Use of nicotine-containing products daily
- Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids.
- Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Los Angeles, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.